insights_auto
Why is 4547 down 3,39%?
Dive Deeperchevron_right
4547:TYO
Kissei Pharmaceutical Co Ltd
3 700,00 JP¥
arrow_downward
-3,39%(-130,00) 1D
2-окт., 15:30:00 GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4547...
Open
3 810 JP¥
High
3 815 JP¥
Low
3 690 JP¥
Mkt. cap
172,21 млд
Avg. vol.
66,55 миң
Volume
97,50 миң
Dividend
3,24%
Quarterly dividend
30 JP¥
Ex-dividend date
2026-ж., 29-сен.
P/E ratio
10,97
52-wk high
5 040 JP¥
52-wk low
3 500 JP¥
EPS
337 JP¥
Shares outstanding
46,72 млн
No. of employees
2 миң
Open
3 810 JP¥
High
3 815 JP¥
Low
3 690 JP¥
Mkt. cap
172,21 млд
Avg. vol.
66,55 миң
Volume
97,50 миң
Dividend
3,24%
Quarterly dividend
30 JP¥
Ex-dividend date
2026-ж., 29-сен.
P/E ratio
10,97
52-wk high
5 040 JP¥
52-wk low
3 500 JP¥
EPS
337 JP¥
Shares outstanding
46,72 млн
No. of employees
2 миң
News stories
From web sources and news partners
Dealroom
·
24 мүнөт мурун
Evernorth clears vote for $1B XRP treasury merger, Nasdaq debut set for October 8
Benzinga
·
57 мүнөт мурун
S&P 500 Index Outlook: Top Catalysts for US Stocks This Week
AD HOC NEWS
·
10 мүнөт мурун
Vicor stock enters October with Q3 guidance above 30 percent
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOMutsuo Kanzawa
Employees1,79 миң
Founded1946-ж., 9-авг.
HeadquartersMatsumoto, Nagano, Япония
SectorPharmaceutical industry
Websitekissei.co.jp